Bozic Carmen 4

What Happened

• Carmen Bozic, Executive Vice President and Chief Medical Officer of Vertex Pharmaceuticals (VRTX), was issued a total of 11,333 shares as earned performance awards on 01/22/2026. The filing shows two award issuances: 7,866 shares and 3,467 shares, each reported at $0.00 per share because they were granted as compensation (not purchased).

Key Details

• Transaction date(s): 2026-01-22; Form 4 filed: 2026-01-26 (timely filing).
• Award details:
  • 7,866 shares: earned under a performance stock unit (PSU) grant originally made 02/01/2023; committee certified performance on 01/22/2026; these shares vest on 02/13/2026. (Footnote F1)
  • 3,467 shares: earned under a PSU grant originally made 02/12/2025; committee certified performance on 01/22/2026; these shares vest in installments beginning 02/24/2026. (Footnote F2)
• Price reported: $0.00 (reflects issuance as compensation, not an open-market purchase).
• Shares owned after the transaction: not provided in the supplied filing details.
• No tax-withholding or sale-for-tax information was included in the provided summary.

Context

• These entries are awards (code A) representing performance-vested shares after the company’s compensation committee certified goal attainment; they are not purchases or sales and therefore do not directly indicate insider buying/selling sentiment. Vesting dates mean the shares become deliverable in February 2026 per the footnotes.